IMR Press / RCM / Special Issues / 1626399489748

Cardiac Hypertrophy: from Basic Science to Clinical Application

Submission deadline: 31 July 2022
Special Issue Editors
Zoltán Papp, MD, PhD
Department of Cardiology, Division of Clinical Physiology, Faculty of Medicine, University of Debrecen, Hungary
Interests: Animal physiology; Signaling pathways; Cardiac function; Physiology; Patch-clamp electrophysiology; Electrophysiology; Cell signaling; Signal transduction; Signaling; Phosphorylation
Attila Kiss, MD
Center for Biomedical Research, Medical University of Vienna, Austria
Interests: Cardioprotection in chronic and acute myocardial ischemia/reperfusion; Mechanism of left ventricular remodeling in cardiovascular disease
Special Issue Information

Dear Colleagues,

 

Indices of myocardial morphology and function should fall within physiological ranges at both the macroscopic and microscopic levels for stable cardiac performance. Accordingly, cardiac chamber sizes together with the characteristics of cardiomyocytes and their subcellular micro-organelles are to be analyzed in combination for the correct interpretation of cardiac health and disease.
Upon various different stress conditions (i.e. hemodynamic pressure- or volume-overload, genetic predispositions, etc.) cardiac muscle enters a transformation process, commonly referred to as cardiac hypertrophy. Thickening of the heart muscle often appears as a compensatory mechanism, nevertheless, concomitant alterations in cardiomyocyte signaling can also limit systolic and/or diastolic functions and evoke life-threatening arrhythmias. In this context, concentric left ventricular hypertrophy has been mostly associated with diastolic dysfunction, leading potentially to heart failure with preserved ejection fraction (HFpEF), while heart failure with reduced ejection fraction (HfrEF) is more often seen in conditions with left ventricular dilation. Nevertheless, making pathophysiological distinctions between HFpEF, HFrEF and the relatively novel category of heart failure with mid-range ejection fraction (HfmrEF) are not without problems. This is due to the high number of overlapping comorbidities and risk factors (e.g. hypertension, atherosclerosis, metabolic derangements, infective-immunological factors, etc.) rarely resulting in pure forms of cardiac pathologies.
Our current view on cardiac remodeling links over-activated neuro-humoral pathways (e.g. the renin-angiotensin-aldosterone system and the beta-adrenergic system) to exhaustive levels of cardiomyocyte receptor stimulations, to an aphysiological function of the intracellular signaling cascades, and ultimately to a modified epigenetic control over cardiomyocytes. One of the hurdles of present time cardiology is the difficulty in finding effective medications acting closer to the distal end of the above chain (i.e. cardiomyocyte nuclei) than to the proximal, like current heart failure medications. In this issue, entitled “Cardiac Hypertrophy: from Basic Science to Clinical Application” we present recent advances in the field of cardiac remodeling and its management to foster preclinical and clinical efforts for the preservation of cardiac integrity and function.

Prof. Dr. Zoltán Papp and Dr. Attila Kiss

Guest Editors

Keywords
Cardiac hypertrophy
Cardiovascular remodeling
Heart failure
Treatment
Prevention
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (5 Papers)
Open Access Review
Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development
Alfredo Caturano, Erica Vetrano, Raffaele Galiero, Teresa Salvatore, ... Ferdinando Carlo Sasso
Rev. Cardiovasc. Med. 2022, 23(5), 165; https://doi.org/10.31083/j.rcm2305165
(This article belongs to the Special Issue Cardiac Hypertrophy: from Basic Science to Clinical Application)
10
Download
41
Views
24
Download
97
Views
6
Download
37
Views
Open Access Communication
Relationship between plasma Neuregulin-1 and cardiac function in patients with ST-elevation myocardial infarction
Paul M Haller, Inês F Gonçalves, Eylem Acar, Bernhard Jäger, ... Bruno K Podesser
Rev. Cardiovasc. Med. 2022, 23(2), 063; https://doi.org/10.31083/j.rcm2302063
(This article belongs to the Special Issue Cardiac Hypertrophy: from Basic Science to Clinical Application)
37
Download
164
Views
Open Access Short Communication
Exercise-induced alterations of myocardial sarcomere dynamics are associated with hypophosphorylation of cardiac troponin I
Beáta Bódi, Attila Oláh, Lilla Mártha, Attila Tóth, ... Zoltán Papp
Rev. Cardiovasc. Med. 2021, 22(4), 1079–1085; https://doi.org/10.31083/j.rcm2204119
(This article belongs to the Special Issue Cardiac Hypertrophy: from Basic Science to Clinical Application)
39
Download
1
Citations
161
Views
Back to top